Publications

VCs keep investing but the scope’s changing!
Financial Advisory Newsletter, 1st Edition
Q1 - 2008
Roadmap for success in oncology
SCRIP Executive Briefing, Vol 1 No 3 The worldwide oncology market is projected to outgrow the rest of the pharma industry, becoming the number one therapeutic class in revenue terms by 2011. So will oncology become pharma’s new “holy grail”?
Dr Frederic Desdouits, Lionel Delaporte and Dr Stéphane Parnis
2008
“Up or Out in Oncology” ­ Executive Summary only
Bionest Disease Area Review
Stéphane Parnis, Guillaume Madec, Lionel Delaporte and Frédéric Desdouits produced the second edition of our annual review related to the outlook of the oncology market. As part of the report, the authors provide advice to bio-pharmaceutical companies on how to develop and sustain a profitable business in this attractive but risky domain. To request the 78-page full report, please contact us.
November, 2007
Net Profit
EBR
Bionest¹s Frédéric Desdouits and Catherine Pichereau compare methods of valuing biotech and find that public markets offer a means to value companies even with as little information as is available on their website.
Autumn, 2007
Innovation takes the prize
Pharmaceutical Executive A celebration of the first annual Prix Galien
Daniel Teper
October, 2007
Vaccines : Growth Boosters
Exane BNP Paribas Equity Research Report
Alain Gilbert, Claude Allary and Frédéric Desdouits
June, 2006
Reaching Maturity – New Challenges for an Evolving Industry
VentureCapital Magazine. (article in German)
Frédéric Desdouits and Christian Hein analyse the current state of the German biotech industry and its future challenges: the need to internationalize and to start commercializing its own products.
April, 2006
Oncology Pipelines – Searching is not Finding
Exane BNP Paribas Equity Research Report
Frédéric Desdouits and Stéphane Parnis, in collaboration with Exane BNP Paribas, have produced an in-depth study of the oncology sector, reviewing the past and forecasting future trends.
March, 2006
Therapeutic Peptides Under the Spotlight
EBR
Catherine Pichereau and Claude Allary explore the challenges, trends and opportunities within a sector receiving increasing attention.
January, 2006
The European Giant Stirs from Slumber
Biotechnologies et Finances
Frédéric Desdouits and Catherine Pichereau review the evolution of the financial landscape of the Biotech industry in 2005.
December, 2005
1 2 3 4 5